印度放棄“印度制造”？向外國疫苗敞開大門
Grady McGregor
2021-04-16
印度衛(wèi)生部周二表示，將放棄完全依賴“印度制造”的新冠肺炎疫苗戰(zhàn)略，接受外國疫苗，以抵御疫情爆發(fā)一來最嚴(yán)重的一波感染。
印度衛(wèi)生部稱，經(jīng)世界衛(wèi)生組織及美國、歐洲、英國、日本監(jiān)管機(jī)構(gòu)批準(zhǔn)的新冠肺炎疫苗自此打開了在印度緊急銷售的大門。
印度衛(wèi)生部在一份聲明中表示:“這一決定將有助于印度提升獲得外國疫苗的速度。”聲明還稱，新政策將有助于印度增加“大宗藥物原材料”進(jìn)口，提高疫苗灌裝產(chǎn)能，從而提升該國新冠肺炎疫苗的整體生產(chǎn)水平。
就在這一決定出臺之時，印度正在抵御自疫情爆發(fā)以來最嚴(yán)重的一波感染。上周，印度單日新增確診病例超過10萬例，系疫情以來首次。確診病例數(shù)還在繼續(xù)上升。周一，印度新增16.8萬例確診病例，創(chuàng)下最高日增記錄。
印度已經(jīng)在孟買等疫情嚴(yán)重地區(qū)實(shí)行了封城措施，試圖管控新一波蔓延。印度政府還嘗試使用兩種“印度制造”的疫苗來助推其剛剛起步的疫苗接種計劃。其中一種疫苗為英國公司阿斯利康(AstraZeneca)開發(fā)，但由印度血清研究所（Serum Institute of India）在當(dāng)?shù)厣a(chǎn)銷售。另一種由印度制藥公司巴拉特生物技術(shù)公司（Bharat Biotech）研發(fā)，已在印度市場批準(zhǔn)使用。
然而，這兩種疫苗無法滿足印度14億人口的需求。
截至周一，該國三分之一的邦都報告疫苗嚴(yán)重短缺，疫苗注射點(diǎn)不得不回絕那些想登記接種的人群。
印度的疫苗接種速度也落后于其他主要經(jīng)濟(jì)體。
截至目前，印度共接種1.08億針疫苗，相當(dāng)于僅有6.9%的印度人注射過至少一針疫苗。相比之下，人口總量為3.28億的美國已為其公眾接種了1.9億針疫苗，意味著36.4%的人口至少已經(jīng)注射了一針。
向外國疫苗敞開大門或?qū)⒂兄诰徑庥《鹊囊呙绻?yīng)困境，至少有一家疫苗制造商似乎已經(jīng)準(zhǔn)備好向印度供貨。
衛(wèi)星5號（Sputnik V）疫苗背后的俄羅斯直接投資基金(Russian Direct Investment Fund)周一表示，或可在4月底開始向印度出口疫苗。
同樣在周一，印度批準(zhǔn)了俄羅斯的衛(wèi)星5號疫苗用于緊急接種。印度政府在聲明中表示，將考慮再批準(zhǔn)100種外國疫苗，進(jìn)一步增加供應(yīng)量。
印度衛(wèi)生部表示，疫苗制造商需要在印度領(lǐng)土上進(jìn)行7天安全試驗，才可以面向公眾接種。（財富中文網(wǎng)）
譯者：Agatha
印度衛(wèi)生部周二表示，將放棄完全依賴“印度制造”的新冠肺炎疫苗戰(zhàn)略，接受外國疫苗，以抵御疫情爆發(fā)一來最嚴(yán)重的一波感染。
印度衛(wèi)生部稱，經(jīng)世界衛(wèi)生組織及美國、歐洲、英國、日本監(jiān)管機(jī)構(gòu)批準(zhǔn)的新冠肺炎疫苗自此打開了在印度緊急銷售的大門。
印度衛(wèi)生部在一份聲明中表示:“這一決定將有助于印度提升獲得外國疫苗的速度。”聲明還稱，新政策將有助于印度增加“大宗藥物原材料”進(jìn)口，提高疫苗灌裝產(chǎn)能，從而提升該國新冠肺炎疫苗的整體生產(chǎn)水平。
就在這一決定出臺之時，印度正在抵御自疫情爆發(fā)以來最嚴(yán)重的一波感染。上周，印度單日新增確診病例超過10萬例，系疫情以來首次。確診病例數(shù)還在繼續(xù)上升。周一，印度新增16.8萬例確診病例，創(chuàng)下最高日增記錄。
印度已經(jīng)在孟買等疫情嚴(yán)重地區(qū)實(shí)行了封城措施，試圖管控新一波蔓延。印度政府還嘗試使用兩種“印度制造”的疫苗來助推其剛剛起步的疫苗接種計劃。其中一種疫苗為英國公司阿斯利康(AstraZeneca)開發(fā)，但由印度血清研究所（Serum Institute of India）在當(dāng)?shù)厣a(chǎn)銷售。另一種由印度制藥公司巴拉特生物技術(shù)公司（Bharat Biotech）研發(fā)，已在印度市場批準(zhǔn)使用。
然而，這兩種疫苗無法滿足印度14億人口的需求。
截至周一，該國三分之一的邦都報告疫苗嚴(yán)重短缺，疫苗注射點(diǎn)不得不回絕那些想登記接種的人群。
印度的疫苗接種速度也落后于其他主要經(jīng)濟(jì)體。
截至目前，印度共接種1.08億針疫苗，相當(dāng)于僅有6.9%的印度人注射過至少一針疫苗。相比之下，人口總量為3.28億的美國已為其公眾接種了1.9億針疫苗，意味著36.4%的人口至少已經(jīng)注射了一針。
向外國疫苗敞開大門或?qū)⒂兄诰徑庥《鹊囊呙绻?yīng)困境，至少有一家疫苗制造商似乎已經(jīng)準(zhǔn)備好向印度供貨。
衛(wèi)星5號（Sputnik V）疫苗背后的俄羅斯直接投資基金(Russian Direct Investment Fund)周一表示，或可在4月底開始向印度出口疫苗。
同樣在周一，印度批準(zhǔn)了俄羅斯的衛(wèi)星5號疫苗用于緊急接種。印度政府在聲明中表示，將考慮再批準(zhǔn)100種外國疫苗，進(jìn)一步增加供應(yīng)量。
印度衛(wèi)生部表示，疫苗制造商需要在印度領(lǐng)土上進(jìn)行7天安全試驗，才可以面向公眾接種。（財富中文網(wǎng)）
譯者：Agatha
India’s Ministry of Health said on Tuesday that it is departing from its “Made in India” COVID-19 vaccine strategy and will accept foreign-made vaccines as the country battles an unprecedented wave of infections.
The announcement opens the door for COVID-19 vaccines—approved by the World Health Organization or regulators in the U.S., Europe, the U.K., or Japan—to be sold in India on an emergency basis, the Ministry of Health said.
“This decision will facilitate quicker access to such foreign vaccines by India,” the Ministry of Health said in a statement. The new policy will also boost India’s COVID-19 vaccine manufacturing capabilities by increasing the country’s “fill and finish” vaccine capacity and opening the door to more imports of “bulk drug material,” the statement said.
The decision comes as India is battling its largest wave of infections since the beginning of the pandemic. Last week, India recorded over 100,000 cases in a single day for the first time since the beginning of the pandemic. Cases have continued to rise. On Monday, India confirmed 168,000 infections, a daily record.
India has instituted lockdowns in hard-hit areas such as Mumbai to help limit the new wave. It also has attempted to boost its fledgling vaccine campaign using two “Made in India” vaccines. One vaccine was originally developed by British firm AstraZeneca, but is manufactured and sold locally via the Serum Institute of India. Indian pharmaceutical firm, Bharat Biotech developed the other COVID-19 vaccine approved in the Indian market.
The two vaccines, however, are failing to meet the demands of India’s 1.4 billion citizens.
As of Monday, one-third of the country’s states were reporting severe vaccine shortages, and vaccine clinics have been forced to turn away people who had signed up for shots.
India has also fallen behind other major economies in delivering the shots.
In total, India has administered 108 million vaccine shots, which amounts to roughly 6.9% of the population receiving at least one jab. The U.S., by contrast, has administered 190 million shots to its 328 million citizens, enough for 36.4% of the population to be injected with at least one shot.
Opening the door to foreign-made vaccines may help alleviate some of India’s vaccine supply woes and at least one vaccine maker appears ready to supply India.
The Russian Direct Investment Fund, which backs the Sputnik V vaccine, said on Monday that it may begin exporting doses to India by late April.
Also on Monday, India approved Russia’s state-backed Sputnik V vaccine for emergency distribution. In the announcement, India’s government said it would now consider adding up to 100 other foreign-made vaccines to further bolster supply.
Vaccine makers will be asked to conduct a seven-day safety trial on Indian soil before any rollout to the public, according to the Ministry of Health.
財富中文網(wǎng)所刊載內(nèi)容之知識產(chǎn)權(quán)為財富媒體知識產(chǎn)權(quán)有限公司及/或相關(guān)權(quán)利人專屬所有或持有。未經(jīng)許可，禁止進(jìn)行轉(zhuǎn)載、摘編、復(fù)制及建立鏡像等任何使用。
